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Like apoptosis, oncogene-induced senescence
is a barrier to tumor development. However, rel-
atively little is known about the signaling path-
waysmediating the senescence response. p38-
regulated/activated protein kinase (PRAK) is a
p38 MAPK substrate whose physiological func-
tions are poorly understood. Here we describe
a role for PRAK in tumor suppression bydemon-
strating that PRAK mediates senescence upon
activation by p38 in response to oncogenic ras.
PRAK deficiency in mice enhances DMBA-
induced skin carcinogenesis, coinciding with
compromised senescence induction. In primary
cells, inactivation of PRAK prevents senes-
cence and promotes oncogenic transformation.
Furthermore, we show that PRAK activates
p53 by direct phosphorylation. We propose
that phosphorylation of p53 by PRAK following
activation of p38 MAPK by ras plays an impor-
tant role in ras-induced senescence and tumor
suppression.
INTRODUCTION
p38MAPKmediatesmultiple cellular processes, including
proliferation, differentiation, inflammation, and stress re-
sponses (Ono and Han, 2000). p38-regulated/activated
protein kinase (PRAK, or MK5) is one member of the p38
downstream Ser/Thr protein kinase family (New et al.,
1998; Shi and Gaestel, 2002). However, PRAK/ mice
display normal LPS-induced cytokine production andendotoxic shock (Shi et al., 2003), suggesting that PRAK
may not be essential for inflammation and stress re-
sponses. The physiological role and downstream target
of PRAK thus remain undefined.
Senescence is a stable proliferative arrest associated
with the exhaustion of replicative potential as a result of
telomere erosion during cell divisions (Shay and Wright,
2005). Telomere length-independent senescence can be
induced prematurely by activated oncogenes such as
ras (Serrano et al., 1997). As a result, cellular transforma-
tion by ras requires cooperation from ‘‘immortalizing’’ on-
cogenes that overcome the senescence response (Land
et al., 1983). These observations imply that, like apoptosis,
premature senescence induced by ras or other oncogenes
serves as an antitumorigenic defensemechanism. Several
recent studies have shown that oncogene-induced senes-
cence indeed occurs and provides an initial barrier to
tumorigenesis in vivo (Collado et al., 2005; Michaloglou
et al., 2005; Braig et al., 2005; Chen et al., 2005).
Despite recent demonstrations of the in vivo signifi-
cance of oncogene-induced senescence, little is known
about the molecular machineries mediating the senes-
cence response. Studies have indicated that the ability
of ras to induce senescence depends on the Raf-MEK-
ERK MAPK pathway (Lin et al., 1998; Zhu et al., 1998)
and is accompanied by upregulation of p16INK4A, p53,
p14/p19ARF, and/or p21WAF1 (Serrano et al., 1997; Fer-
beyre et al., 2002) and silencing of E2F target genes
(Narita et al., 2003). Transcriptional activation of p19ARF
by DMP1 (Sreeramaneni et al., 2005) also contributes to
ras-induced senescence. Recently, we and others have
shown that ras-induced senescence requires activation
of p38 (Wang et al., 2002; Iwasa et al., 2003; Haq et al.,
2002). However, it remains unclear how activated p38
transduces the senescence signals. More importantly,Cell 128, 295–308, January 26, 2007 ª2007 Elsevier Inc. 295
the role of the p38 pathway in senescence and tumor
suppression in vivo remains elusive.
In this study, we uncover a novel function of PRAK in
tumor suppression and ras-induced senescence. PRAK
deficiency leads to increased skin carcinogenesis in mice
and renders primary cells more susceptible to oncogenic
transformation. The tumor-suppressing effect of PRAK is
likely due to its ability to mediate ras-induced senescence,
by modulating p53 activity through direct phosphoryla-
tion. Our studies define a signaling cascade that plays
an essential role in ras-induced senescence and tumor
suppression.
RESULTS
Targeted Deletion of PRAK Promotes Skin
Carcinogenesis in Mice
Wegenerated a line ofPRAK knockoutmice (see Figure S1
in the Supplemental Data available with this article online),
which were viable and fertile and showed no apparent
health problems. Although PRAK is activated by p38 in
response to stresses (New et al., 1998), the PRAK/
mice responded normally to endotoxin shock and showed
unaltered cytokine production in response to LPS (unpub-
lished data), suggesting that PRAK may not be essential
for inflammatory responses.
In search of phenotypes of PRAK/mice, we assessed
the susceptibility of PRAK+/+, PRAK+/, and PRAK/
mice to skin carcinogenesis induced by a well-character-
ized mutagen, dimethylbenzanthracene (DMBA). DMBA-
induced skin carcinogenesis is divided into three stages:
initiation (induction of stable oncogenic mutations, such
as ras activation, by DMBA), promotion (proliferation of
genetically altered cells), and progression (conversion of
papillomas to invasive carcinomas) (DiGiovanni, 1992). In
the presence of a tumor promoter such as TPA (two-stage
protocol), DMBA induces efficient skin tumor formation,
while without TPA (one-stage protocol), DMBA-induced
tumor formation is poor in most strains.
The PRAK-deficient mice were initially analyzed using
the one-stage protocol, which has been successfully
used to demonstrate the tumor-suppressing function of
several senescence-related genes such as the INK4a
locus (Serrano et al., 1996), p19ARF (Kamijo et al., 1999),
and DMP1 (Inoue et al., 2001). Newborn PRAK+/+,
PRAK+/, and PRAK/ littermates from heterozygous
crosses were treated with a single dose of DMBA and
monitored for a year (Figure 1A). DMBA alone induced
tumor formation poorly in wild-type mice. Only 1 of 12
DMBA-treated PRAK+/+ mice developed a skin papilloma.
In contrast, 8 of 13 (62%) DMBA-treated PRAK/ mice
displayed health problems, out of which 7 developed
skin papillomas and 1 died of unidentified causes
(Figure 1A). DMBA also induced papillomas in 12 of 30
(40%) PRAK+/ mice within the same period. In the un-
treated control groups, all 9 PRAK+/+, 25 PRAK+/, and
10 PRAK/ animals remained healthy and tumor-free
for at least 2 years (data not shown). Therefore, PRAK296 Cell 128, 295–308, January 26, 2007 ª2007 Elsevier Inc.deficiency greatly enhances DMBA-induced skin carcino-
genesis and allows efficient tumor induction in the
absence of any tumor promoter, suggesting that PRAK
loss can functionally replace a tumor promoter. Support-
ing this notion, PRAK deficiency had no effect on the
incidence or latency of skin tumors induced by the two-
stage protocol (Figure S2A). In the presence of the tumor
promoter TPA, DMBA induced skin papillomas in 6 of 7
wild-type mice and 14 of 16 PRAK-deficient (PRAK+/
and PRAK/) mice, with an average latency of 70–100
days. Taken together, our results suggest that PRAK
may act in a pathway that suppresses the tumor promo-
tion stage during DMBA-induced skin carcinogenesis.
The tumor-suppressing activity of PRAK is likely to be
specific for ras because PRAK deficiency also enhanced
lymphomagenesis in Em-N-rasG12D transgenic mice (Fig-
ure 1B). Tumor-free survival was significantly reduced
in Em-N-ras/PRAK+/ mice from Em-N-ras/PRAK+/+ 3
PRAK+/ crosses as compared to their Em-N-ras/PRAK+/+
littermates. A similar trend of enhanced lymphoma forma-
tion was also observed in a limited number of Em-N-ras/
PRAK/ mice from Em-N-ras/PRAK+/ 3 Em-N-ras/
PRAK+/ crosses.
Since both PRAK+/ and PRAK/ mice were highly
susceptible to skin carcinogenesis induced by DMBA
alone (Figure 1A), we investigated whether the wild-type
PRAK allele was lost in PRAK+/ papillomas. Western
blot and immunohistochemical analyses revealed that
PRAK+/ tumors and their surrounding normal skin tissues
had comparable levels of PRAK (Figures 1C and 1D),
indicating that PRAK expression is retained in PRAK+/
tumors. Thus, PRAK is haploinsufficient for tumor
suppression.
Senescence Induction Is Compromised in Skin
Tumors from PRAK-Deficient Mice
Over 90% of DMBA-induced skin tumors contain acti-
vated Ha-ras (Quintanilla et al., 1986). Thus, our observa-
tion that PRAK deficiency promotes DMBA-induced skin
carcinogenesis raises the possibility that PRAK is essen-
tial for an in vivo tumor-suppressing mechanism against
activated ras. Since oncogene-induced senescence is
a barrier to tumorigenesis in vivo and p38 plays a major
role in ras-induced senescence (Wang et al., 2002), we
investigated whether enhanced skin carcinogenesis
resulted from a defect in senescence induction in PRAK-
deficient mice.
The skin tumors induced by DMBA or DMBA+TPA in all
the animals were superficial papillomas consisting of an
inner connective tissue vascular core, a stratified squa-
mous epithelium with basal cells, and an outer surface of
keratin (Figure 1E and Figure S2B; H/E). Only one of the
DMBA-induced PRAK+/ papillomas progressed to
a malignant carcinoma, 5 months after initial detection.
While the tumors induced by DMBA in PRAK/ and
PRAK+/ mice grew slowly but progressively and usually
reached a size of more than 10 mm in diameter within
2–3 months of initial detection, the DMBA-induced tumor
Figure 1. PRAK Deficiency Promotes Skin Carcinogenesis and Compromises Senescence Induction in Skin Tumors
(A) Tumor-free survival in PRAK+/+, PRAK+/, and PRAK/ littermates treated with DMBA in one-stage carcinogenesis. p < 0.01 in log-rank test.
(B) PRAK deficiency accelerates lymphoma formation in Em-N-rasG12D transgenic mice. Tumor-free survival of PRAK+/+, PRAK+/, and PRAK/mice
carrying the Em-N-rasG12D transgene. The number of animals and the p values for log-rank tests comparing each group to wild-type mice are shown.
(C)Westernblot detectingPRAKandactin in aDMBA-inducedPRAK+/papilloma (P) andadjacent normal skin (NS) and inPRAK+/+ andPRAK/ skins.
(D) Analysis of PRAK levels by immunohistochemistry in a DMBA-induced PRAK+/ papilloma (P) and adjacent normal skin (NS).
(E) Expression of SA-b-gal and immunohistochemical analysis of indicated protein levels in DMBA-induced papillomas from the indicated genotypes.
See Figure S3A for additional sections of SA-b-gal-positive wild-type tumors.from the wild-type mouse seemed to be dormant and
remained at about 2–3 mm in diameter after 2 months
(data not shown). Compared to the wild-type tumors,
DMBA-induced PRAK-deficient papillomas also had
more complicated structures, with much thicker and
more folded layers of squamous epithelium (Figure 1E).
We analyzed senescence and proliferative markers in
tumors removed from animals treated with DMBA alone.
The PRAK+/+ papilloma contained large areas of cells
positive for the senescence-associated b-galactosidase
(SA-b-gal) marker in squamous epithelium, whereas SA-
b-gal was undetectable in PRAK+/ and PRAK/ tumors
(Figure 1E and Figures S3A and S3B). The absence of
SA-b-gal in PRAK-deficient tumors was not a result of ageneral defect in this enzyme due to PRAK deletion, as
it was readily detectable in normal skin from adult mice
of all three genotypes, including skin adjacent to the
PRAK-deficient papillomas (Figure S3C). Other senes-
cencemarkers, including those identified in a recent study
(Collado et al., 2005), were further examined. In western
blot analysis, expression of p16INK4A, DcR2, and Dec1
was increased in the PRAK+/+ papilloma in comparison
to in adjacent normal skin, while these increases were
abolished in PRAK+/ (Figure S4) and PRAK/ (data not
shown) tumors. The absence of induction of the senes-
cence markers was confirmed in both PRAK+/ and
PRAK/ tumors by immunohistochemistry (Figure 1E).
The majority of the cells in the squamous epithelium ofCell 128, 295–308, January 26, 2007 ª2007 Elsevier Inc. 297
the PRAK+/+ tumor, including undifferentiated and differ-
entiated basal cells, were negative for the proliferation
marker Ki-67 but positive for p16INK4A and DcR2, indicat-
ing that these cells were growth arrested and senescent.
In contrast, most cells in the basal layers of PRAK+/ and
PRAK/ papillomas were positive for Ki-67 but negative
for DcR2 and p16INK4A, and only the denucleated, highly
differentiated cells immediately adjacent to keratin con-
tained high DcR2 and p16 levels. Therefore, senescence
induction is compromised in PRAK-deficient tumors.
Taken together, our results suggest that DMBA-induced
skin carcinogenesis is initially restricted by senescence
in wild-type mice, which prevents papilloma formation
and/or keeps the tumors indormancyupon their formation.
PRAK deletion compromises senescence induction, lead-
ing to increased incidence and more efficient formation
of DMBA-induced tumors.
The senescence markers were also analyzed in the
DMBA+TPA-induced tumors. While the DMBA+TPA-in-
duced PRAK-deficient tumors had no detectable SA-b-
gal and were essentially negative for DcR2 and p16INK4A
in the underdifferentiated layers of the squamous epithe-
lium, the wild-type tumors contained patches of cells
weakly positive for DcR2 and p16INK4A and a few small
SA-b-gal-positive areas (Figure S2B). However, both
wild-type and PRAK-deficient tumors contained substan-
tial amounts of Ki-67-positive cells in the squamous epi-
thelium (Figure S2B) and seemed to grow slowly but
steadily. Thus, at least a substantial portion of the wild-
type tumor is proliferative and might have bypassed se-
nescence in the presence of the tumor promoter TPA. It
is unclear how TPA allows proliferation of cells containing
activated ras in wild-type tumors and whether TPA truly
disrupts senescence in these cells. TPA did not prevent
ras-induced senescence in primary fibroblasts (data not
shown). Nevertheless, the reduced levels of the senes-
cence markers in the DMBA+TPA-induced wild-type tu-
mors as compared to theDMBA-inducedwild-type tumors
(Figure 1E and Figure S2B) are consistent with a role of
PRAK-mediated senescence in suppressing the tumor
promotion stage during skin carcinogenesis.
PRAK Is Essential for ras-Induced Senescence
in Primary Murine and Human Fibroblasts
To further establish the essential role of PRAK in ras-
induced senescence responses, we examined the role
of PRAK in ras-induced senescence in primary cells.
PRAK+/+ primary mouse skin fibroblasts (MSFs) became
growth arrested (Figure 2A) and accumulated SA-b-gal
(Figure 2C) upon transduction of an activated ras allele,
Ha-RasV12 (Figure 2B), indicating that ras triggered
premature senescence. By contrast, Ha-RasV12-induced
proliferative arrest or the SA-b-gal marker was abolished
in PRAK/ cells and partially blocked in PRAK+/ cells
(Figures 2A and 2C). Therefore, the deletion of PRAK com-
promised the senescence response in primary MSFs.
Similarly, PRAK deletion abolished ras-induced senes-
cence in primary mouse embryonic fibroblasts (MEFs)298 Cell 128, 295–308, January 26, 2007 ª2007 Elsevier Inc.(Figure 2D and Figure S5A). Supporting the disruption of
ras-induced senescence in PRAK-deficient cells, the induc-
tion of the senescence markers DcR2, Dec1, p16INK4A, and
p19ARF by ras was either modestly or greatly reduced in
PRAK+/ and PRAK/ MEFs when compared to wild-
type cells (Figure S5C). The disruption of ras-induced
senescence was a specific result of the loss of PRAK be-
cause wild-type PRAK, but not its kinase-dead mutant
(KM) (Lys51 to Met), restored the senescence response
when reintroduced into the PRAK/ MEFs (Figure 2D).
These findings demonstrate that PRAK is essential for
the ras-induced senescence response in primary mouse
fibroblasts.
The requirement of PRAK in ras-induced senescence
was further investigated in primary human fibroblasts.
Two PRAK shRNAs, shPK-1 and -2, reduced PRAK ex-
pression (Figure 3A) and ras-induced PRAK kinase activity
when stably transduced into BJ human fibroblasts
(Figure 3B). These two PRAK shRNAs prevented Ha-
RasV12-induced proliferative arrest (Figure 3C) and accu-
mulation of SA-b-gal (Figure 3DandFigure S5A). The same
results were obtained in BJ cells at amuch earlier passage
(PD15, passage 6) or when a scrambled shPK-1 sequence
wasusedascontrol (FigureS6). Thus,PRAK is essential for
ras to induce premature senescence in primary human
fibroblasts. The induction of a recently identified senes-
cence marker, p15INK4B, by ras was also abolished in BJ
cells with PRAK knockdown (Figure S5D).
To rule out a possible off-target effect of PRAK shRNAs
on senescence, murine PRAK (mPRAK) that could not be
silenced by shPK-1 and shPK-2 (Figure 3E) was trans-
duced into BJ cells to rescue PRAK expression. mPRAK
restored ras-induced senescence in BJ cells expressing
PRAK shRNA, but not in cells with p53 knockdown (Fig-
ures 3C and 3D). These results indicate that the bypass
of ras-induced senescence in BJ cells is due to specific
silencing of PRAK. In contrast to p53 shRNA, PRAK
shRNA did not prevent G1 arrest induced by g-irradiation
or UV light (Figure S7A), suggesting that PRAK is selec-
tively required for ras-induced senescence, but not for
DNA-damage-induced responses.
PRAK Deficiency Promotes Cellular Transformation
We further tested whether disrupting the senescence re-
sponse by PRAK deficiency would permit transformation
by ras alone in the absence of immortalizing oncogenes.
Similar to p53/ primary MSFs, primary PRAK/ MSFs
and MEFs were not tumorigenic by themselves but were
readily transformed into tumorigenic cells by Ha-RasV12
alone, which formed robust colonies without anchorage
and produced subcutaneous tumors with high frequency
when injected into nude mice (Figure 4A). PRAK+/ cells
were also transformed, although less efficiently, by Ha-
RasV12 (data not shown). These results demonstrate
that eliminating PRAK renders primary murine fibroblasts
susceptible to oncogenic transformation by ras.
BJ primary human fibroblasts can be fully trans-
formed by a combination of E1A, MDM2, and Ha-RasV12
Figure 2. PRAK Is Essential for ras-Induced Senescence in Primary Murine Fibroblasts
(A) Population doublings of PRAK+/+ (WT42), PRAK+/ (HT7 and HT27), and PRAK/ (KO3 and KO31) primary mouse skin fibroblasts (MSFs)
transduced with Ha-RasV12 (Ras) or vector (VT) at passage 2 were followed over 13 days.
(B) Western blots detecting Ras and actin in the same MSFs.
(C) Percentage of SA-b-gal-positive cells in the sameMSFs on day 8 post ras transduction. *p < 0.005; #p < 0.01 versusWT42+Ras by Student’s t test.
Values are mean ± standard deviation (SD) for duplicates in (A) and (C).
(D) Population doublings of two lines of PRAK/ primary mouse embryonic fibroblasts (MEFs) (KO12 and KO16) cotransduced with Ha-RasV12 and
PRAK, PRAK-KM, or vector (VT) at passage 3 were followed over 12 days.(Seger et al., 2002) (Figure 4B). We tested whether PRAK
knockdown could replace any of the oncogenes in this
cellular transformation model. PRAK shRNA alone or in
combination with Ha-RasV12 or Ha-RasV12 and MDM2
did not cause transformation. Interestingly, BJ cells trans-
duced with E1A, PRAK shRNA, and Ha-RasV12 formed
soft-agar colonies and generated subcutaneous tumors
as efficiently as the BJ/E1A/MDM2/Ha-RasV12 cells (Fig-
ures 4B and 4C). As noticed by others (Seger et al., 2002),
BJ cells expressing E1A and Ha-RasV12 formed amodest
amount of small colonies on soft agar, but they were not
fully transformed because they did not develop tumors
in nudemice (Figures 4B and 4C). Therefore, PRAK knock-
down functionally replaced MDM2 and cooperated withE1A and Ha-RasV12 to transform normal human fibro-
blasts.
PRAK Kinase Activity Is Induced in Senescent Cells
in a p38-Dependent Manner
We determined whether the PRAK kinase activity was
induced in senescent cells using HSP27 as a substrate.
PRAK protein was immunoprecipitated from either wild-
type BJ cells or BJ cells undergoing premature senes-
cence induced by either Ha-RasV12 or constitutively
active MKK3 or MKK6. PRAK from senescent cells dis-
played an increased kinase activity in comparison to
that from wild-type BJ cells (Figure 5A). ras-induced
PRAK activation was also detected in primary MEFsCell 128, 295–308, January 26, 2007 ª2007 Elsevier Inc. 299
Figure 3. PRAK Is Essential for ras-
Induced Senescence in Primary Human
Fibroblasts
(A) Western blot (top) and quantitative RT-PCR
(bottom) analysis detecting PRAK expression
in BJ cells transduced with shPRAK (shPK-1
and -2) or shGFP. Relative PRAK RNA levels
are shown after normalization to actin levels.
(B) Endogenous PRAK immunoprecipitated
from BJ cells at PD36.5 on day 7 after trans-
duction of Ha-RasV12 (Ras) or vector (VT) into
cells expressing shPK-1, shPK-2, or shGFP
was assayed for kinase activity toward
HSP27. Relative phosphorylation levels of
substrates and HSP27 input are shown.
(C) Population doublings of BJ cells trans-
duced with shPK-1, shPK-2, shp53, or shGFP;
then with mPRAK or vector (VT); and finally with
Ha-RasV12 (Ras) or vector were followed over
16 days, starting from PD30.
(D) Percentage of SA-b-gal-positive cells in the
same cell populations on day 6 post ras trans-
duction. *p > 0.05; #p < 0.05 versus respective
non-ras control by Student’s t test. Values are
mean ± SD for duplicates in (C) and (D).
(E) Western blot detecting indicated protein
levels in specified BJ cells.(Figure 5B). ras- and MKK3/6E-induced PRAK kinase
activity was greatly reduced in both BJ and MEF cells
by a specific p38 inhibitor, SB203580 (Figures 5A and
5B). This, combined with our previous finding that p38
is activated during senescence (Wang et al., 2002), indi-
cates that PRAK is activated by p38 during ras-induced
senescence.
Furthermore, PRAK and p38 immunoprecipitated from
the DMBA-induced papilloma in the wild-type mouse300 Cell 128, 295–308, January 26, 2007 ª2007 Elsevier Inc.also showed increased kinase activity toward their sub-
strates, HSP27 and ATF2 respectively, in comparison to
the proteins isolated from normal skin in the same mouse
(Figure 5C). Since this tumor displayed senescence fea-
tures (Figure 1E and Figure S4), our results confirm that
PRAK and p38 are activated in senescent cells in vivo,
and they are consistent with the essential role of these
kinases in establishing the senescence response in
DMBA-induced tumors.
Figure 4. PRAK Deficiency Promotes Oncogenic Transformation of Primary Human and Mouse Cells
(A and B) Wild-type, PRAK/, or p53/MSF or MEF cells transduced with Ha-RasV12 or vector at passage 2 (A) and BJ cells transduced at PD18.9
with the indicated oncogenes (B) were assayed for tumorigenesis. Bar graphs represent the number of colonies on soft agar from 4 3 106 cells
3 weeks after seeding. Values are mean ± SD for triplicates within one experiment. The tables show the number of subcutaneous tumors arising
per number of injections within 10 weeks, as combined from several different experiments.
(C) Representative fields of soft-agar colonies formed by the indicated BJ cells.PRAK Overexpression Enhances ras-Induced
Senescence
Since ectopically expressed HA-PRAK is activated in BJ
cells by Ha-RasV12 and MKK3E in a manner similar to
endogenous PRAK (Figure S8), overexpression of PRAK
should enhance PRAK-mediated signaling. Therefore,
we investigated the consequences of PRAK overexpres-
sion on senescence. Overexpression of wild-type PRAK
caused a slight reduction in cell proliferation rate without
a detectable increase in the SA-b-gal marker (Figures 5D
and 5E). Thus, PRAK alone was not sufficient to induce
premature senescence, possibly due to the lack of up-
stream signals that activate PRAK. Indeed, Ha-RasV12
induced more robust senescence phenotypes in con-
junction with overexpressed PRAK than by itself. When
compared with Ha-RasV12 alone, coexpression of Ha-
RasV12 with PRAK resulted in stronger growth inhibition
(Figure 5D) and twice as many SA-b-gal-positive cells
on day 7 after ras transduction (Figure 5E). PRAK also
enhanced cell enlargement, another characteristic of se-
nescence (Figure S9A). By contrast, no difference was
observed in the percentage of apoptotic cells between
these two populations (Figure S9B), indicating that the
stronger growth inhibition in PRAK/Ha-RasV12 cellsCresulted from enhanced senescence but not increased
apoptosis. The effect of PRAK on senescence requires
its activation and its kinase activity since the activation-
site mutant (T182A) and the kinase-dead mutant (KM) of
PRAK (New et al., 1998) failed to enhance ras-induced
senescence (Figures 5D and 5E and Figure S9A), even
though their levels of expression were comparable to
wild-type PRAK (Figure 5F). These results demonstrate
that PRAK is a rate-limiting factor during senescence in
BJ cells and that an increase in PRAK expression levels
sensitizes cells to ras-induced senescence.
PRAK Is Essential for Senescence-Induced p53
Transcriptional Activity
ras-induced senescence ismediated by sequential activa-
tion of the ERK and p38 pathways (Wang et al., 2002);
hypophosphorylation of pRb; and silencing of E2F targets
such as PCNA, MCM3, and cyclin A (Serrano et al., 1997;
Narita et al., 2003). In an attempt to determine the signal-
ing step on which PRAK acts, we found that PRAK knock-
down in BJ cells did not alter activation of ERK or p38 by
ras (Figure 6A) but prevented the silencing of the E2F
targets PCNA, MCM3, and cyclin A (Figure 6B). Thisell 128, 295–308, January 26, 2007 ª2007 Elsevier Inc. 301
Figure 5. PRAK Kinase Activity Is Induced by p38 in Senescent Cells, and Increased PRAK Expression Enhances ras-Induced
Senescence
(A and B) Endogenous PRAK was immunoprecipitated from BJs at PD31 on day 7 (A) or from MEFs at passage 3 on day 6 (B) after transduction of
Ha-RasV12, MKK3E, MKK6E, or vector and treatment with 8 mM SB203580 or vehicle and assayed for kinase activity toward HSP27.
(C) PRAK and p38 immunoprecipitated from the DMBA-induced papilloma and adjacent normal skin in a wild-type mouse were assayed for kinase
activity toward HSP27 and ATF2, respectively. For (A)–(C), western blot analysis was performed to detect indicated proteins in IPs and lysates.
Relative phosphorylation levels of substrates and substrate input are shown.
(D) Population doublings of BJ cells transduced with HA-PRAK or vector (VT) and Ha-RasV12 or vector (VT) were followed over 7 days, starting at
PD33.5.
(E) Percentage of SA-b-gal-positive cells in the same BJ lines on day 6 post ras transduction. *p > 0.05; #p < 0.01 versus VT+Ras by Student’s t test.
Values are mean ± SD for duplicates in (D) and (E).
(F) Western blot detecting indicated proteins in the same BJ cells.indicates that PRAK functions between p38 and E2F
during senescence.
The ability of PRAK shRNA to replaceMDM2, a negative
p53 regulator, in transforming BJ cells (Figure 4B) raises
the possibility that PRAKmaymediate ras-induced senes-
cence by targeting p53. Thus, we examined whether
PRAK was required for oncogenic ras-induced p53 tran-
scriptional activity using a retrovirus-based, stable lucifer-
ase reporter system for p53 (Deng et al., 2005). In both BJ
andwild-typeMEF cells containing this p53 reporter, lucif-
erase activity was stimulated significantly by Ha-RasV12
or MKK3E (Figure 6C), confirming the induction of p53
transcriptional activity in senescence. ras- and MKK3-in-
duced p53 activity was greatly reduced in PRAK-deficient
BJ and MEF cells. Neither Ras/MKK3E nor the PRAK
shRNA significantly altered the transcription of MG-Luc,302 Cell 128, 295–308, January 26, 2007 ª2007 Elsevier Inc.a control reporter containing mutant p53 binding sites
(Deng et al., 2005) (data not shown), indicating that the
effects we observed were specific for p53. The regulation
of p53 activity by PRAK during senescencewas confirmed
by the observation that ras-induced expression of p21WAF1,
an endogenous p53 target previously implicated in ras-
induced senescence, was abolished in PRAK-deficient
BJ and MEF cells (Figure 6D). By contrast, PRAK shRNA
did not block the induction of p53 activity or p21WAF1 ex-
pression by UV (Figures S7B and S7C), in concordance
with the observation that PRAK was not required for
DNA-damage-induced G1 arrest (Figure S6A).
Together, these results suggest that PRAK mediates
ras-induced senescence by stimulating p53 activity, which
in turn increases p21WAF1 expression. Supporting the im-
portance of the PRAK-p53-p21 cascade in senescence
Figure 6. PRAK Is Essential for ras-
Induced p53 Activity in Senescent Cells
(A and B) Western blot detecting indicated
proteins in indicated BJ cells at PD38 on day
8 (A) or PD40 on day 7 (B) post ras transduction.
(C) BJ cells with a stable p53-dependent
reporter and transduced with shPK-1, shPK-
2, shp53, or shGFP (left) or PRAK+/+ (WT51
and WT52), PRAK+/ (HT35), and PRAK/
(KO40 and KO41) MEFs with the stably inte-
grated p53-dependent reporter (right) were
transduced with Ha-RasV12, MKK3E, or vec-
tor. Luciferase activity was measured at PD31
on day 9 (BJ) or at passage 3 on day 7 (MEF)
and normalized to protein concentrations.
Values are mean ± SD for triplicates.
(D) Western blot detecting indicated proteins in
BJ cells expressing specified shRNAs at PD31
on day 8 or PRAK+/+ (WT), PRAK+/ (HT), or
PRAK/ (KO) MEFs at passage 4 on day 8
posttransduction of Ha-RasV12 or vector.in vivo, p21 levels were increased in the DMBA-induced
papilloma when compared to the adjacent normal skin in
wild-type mice, but not in the PRAK-deficient tumors in
which senescence response had been compromised
(Figure S4).
PRAK Phosphorylates p53 at Ser37
The control of p53 activity by PRAK seems to be indepen-
dent of the induction of p53 protein levels. In BJ cells,
PRAK-dependent stimulation of p53 activity by ras
occurred without any detectable increase in p53 protein,
while in PRAK-deficient MEFs, ras failed to enhance p53
activity despite unaltered induction of the p53 protein
(Figure 6D). Thus, PRAK may regulate p53 activity via
posttranslational modifications.
We explored whether PRAK directly phosphorylates
p53. HA-tagged PRAK immunoprecipitated from BJ cells
transduced with Ha-RasV12, MKK3E, or MKK6E readily
phosphorylated human p53 in vitro (Figure 7A). Deletion
analysis of p53 revealed that activated PRAK phosphory-
lates human p53within theN-terminal TAD (residues 1–61)
(Figure 7B). Unlike wild-type PRAK, the kinase-deadmutant (KM) and the activation-site mutant (T182A)
isolated from ras- or MKK3-expressing cells failed to
phosphorylate p53 (Figure 7B).
Recombinant PRAK phosphorylated p53(1–61) in vitro
(Figure 7C, insert), indicating that p53 is a direct substrate
of PRAK. To identify the PRAK phosphorylation site in p53,
p53(1–61) phosphorylated by PRAK was subjected to
phosphopeptide mapping by mass spectrometry (Fig-
ure 7C). Spectrum searches revealed a significant number
of phosphopeptides that contained phospho-Ser37, but
none containing the other phosphoresidues, indicating
that Ser37 is the only site of phosphorylation by PRAK.
Confirming this notion, mutation of Ser37 to Asp essen-
tially abolished phosphorylation by recombinant PRAK or
PRAK immunoprecipitated from senescent cells, while
mutations of Ser15 or Ser33 had no effect on p53 phos-
phorylation (Figures 7D and 7E). The S37D protein was
accessible to kinases since it was readily phosphorylated
by recombinant and immunoprecipitated p38 at Ser33
(Figure S10), as previously reported (Bulavin et al., 1999).
Ser37 of p53 is a conserved residue in mammals (Fig-
ure 7F). The N-terminal TAD of murine p53 (residuesCell 128, 295–308, January 26, 2007 ª2007 Elsevier Inc. 303
Figure 7. PRAK Phosphorylates p53 at Ser37
(A) HA-PRAK immunoprecipitated from BJ cells transduced with HA-PRAK or vector (VT) and Ha-RasV12, MKK3E, MKK6E, or vector (VT) at PD33 on
day 6 post ras transduction was assayed for kinase activity toward GST-full-length hp53.
(B) HA-PRAK immunoprecipitated from BJ cells transduced with wild-type or mutant HA-PRAK or vector (VT) and Ha-RasV12, MKK3E, or vector (VT)
at PD37 on day 6 post ras transduction was assayed for kinase activity toward hp53(1–61) or HSP27.
(C) hp53(1–61) phosphorylated by His-PRAK or left unphosphorylated (insert) was subjected to phosphopeptide analysis by mass spectrometry. The
counts of the MS2 and MS3 spectra representing phosphopeptides were combined for each S/T residue along hp53(1–61).
(D) HA-PRAK immunoprecipitated from BJ cells transduced with HA-PRAK or vector (VT) and Ha-RasV12, MKK3E, or vector (VT) at PD29 on day
7 post ras transduction was assayed for kinase activity toward wild-type or mutant hp53(1–61).
(E) Phosphorylation of wild-type or mutant hp53(1–61) by His-PRAK.
(F) Amino acid sequence alignment of part of the N-terminal TAD of p53 from the indicated species is shown at top. Phosphorylation of wild-type or
mutant mp53(1–57) by His-PRAK is shown below.
(G) Endogenous p53 was immunoprecipitated from BJ cells transduced with shPRAK (shPK) or shGFP and Ha-RasV12 (Ras), MKK3E, or vector (VT)
or treated with 30 J/m2 of UV light at PD30 on day 6 post ras transduction. Indicated proteins were detected by western blotting in IP and lysates.304 Cell 128, 295–308, January 26, 2007 ª2007 Elsevier Inc.
induced senescence (Ferbeyre et al., 2002; Bulavin1–57) was readily phosphorylated by PRAK. The S37D
mutation, but not the mutation of Ser18 (equivalent to
Ser15 in hp53), disrupted phosphorylation of mp53 by
PRAK (Figure 7F), indicating that Ser37 of mp53 is also
the phosphorylation site of PRAK.
In primary BJ cells, Ha-RasV12 or MKK3E increased
phosphorylation of p53 at Ser37, and PRAK knockdown
abrogated ras- and MKK3E-induced S37 phosphorylation
(Figure 7G), while the protein level of p53 was not signifi-
cantly altered. The same results were obtained with two
independent PRAK shRNA constructs (data not shown).
These results demonstrate that, in vivo, PRAK mediates
Ser37 phosphorylation during ras-induced senescence.
We examined mp53 phosphorylation in MEFs trans-
duced with a FLAG-tagged mp53 after metabolically
labeling the cells with 32P-orthophosphate and immuno-
precipitating mp53 (Figure 7H). To avoid the growth inhibi-
tion resulting from stable p53 expression, an mp53 cDNA
containing an A135V mutation was used. In wild-type
MEFs, Ha-RasV12-induced mp53 phosphorylation was
significantly reduced when Ser37 was mutated to Ala,
indicating that Ser37 was one of the ras-induced phos-
phorylation sites. In PRAK/ MEFs, ras-induced mp53
phosphorylation was lower than in the wild-type cells.
More importantly, the S37A mutation did not further re-
duce mp53 phosphorylation, suggesting that PRAK is
responsible for ras-induced phosphorylation of Ser37 in
MEFs. Furthermore, PRAK immunoprecipitated from the
wild-type papilloma had an increased kinase activity
toward Ser37 of mp53 when compared to PRAK from
the adjacent normal skin (Figure 7I). This indicates that
Ser37 is likely phosphorylated by activated PRAK in
tumors that display senescence features.
To analyze the contribution of Ser37 to ras-induced se-
nescence, the effect of ectopic expression of the p53S37A
mutant was examined. To avoid growth inhibition by high
p53 expression levels from the conventional pBabePuro
vector, we used a binary retroviral vector (Deng et al.,
2004) to express p53 at levels that were only 2- to 3-fold
higher than the endogenous protein (Figure S11A) and
did not cause significant growth inhibition in BJ cells (Fig-
ure S11B). Ha-RasV12 caused a stronger growth arrest
(Figure S11B) in BJ cells expressing wild-type p53 than
in control BJ cells, indicating an enhancement of ras-
induced senescence by p53. p53 did not affect the rate
of apoptosis in the presence or absence of ras (Fig-
ure S12). The ability of p53 to enhance ras-induced senes-
cence was abolished by the S37Amutation (Figure S11B),
supporting a key role of PRAK-mediated p53 phosphory-
lation in senescence. Mutation of Ser15 and Ser33, the
other two sites shown to be phosphorylated during ras-et al., 2002), also disrupted the enhancement of senes-
cence. Therefore, p53-mediated senescence may rely
on phosphorylation of multiple sites.
DISCUSSION
Although the requirement of p38 in ras-induced senes-
cence suggests a potential tumor-suppressing function
of this pathway, a direct assessment of the consequences
of p38 inactivation on tumorigenesis in vivo has been diffi-
cult, due partly to the embryonic lethality of p38 knockout
in animals. Supporting an anti-oncogenic role of p38, dele-
tion of a multifunctional p38 phosphatase, Wip1, sup-
presses mammary tumor development in mice (Bulavin
et al., 2004). Our finding of enhanced skin carcinogenesis
upon PRAK deletion demonstrates that the p38 pathway
functions throughPRAK to suppress tumorigenesis.More-
over, we show that increased tumor induction by DMBA
is accompanied by compromised senescence induction
in PRAK-deficient mice, suggesting that PRAK-mediated
senescence is a barrier to skin carcinogenesis in vivo.
Our data suggest that PRAK-mediated senescence
likely suppresses skin carcinogenesis at the tumor promo-
tion stage. Since tumor promotion, by definition, involves
proliferation of genetically altered cells such as those
containing activating ras mutations, it is conceivable that
ras-induced senescence is a major barrier in this step,
which needs to be disrupted for efficient tumor induction.
In the mouse strain (129 3 C57BL/6) used in our study,
PRAK did not significantly increase the rate of papilloma-
to-carcinoma conversion. However, since the papilloma-
to-carcinoma conversion rate is extremely low in this
background, we cannot exclude the possibility that PRAK
deletion enhances progression in other strains with higher
conversion rates.
In contrast to p53- and p19ARF-deficient mice (Jacks
et al., 1994; Donehower et al., 1992; Kamijo et al., 1999),
PRAK-deficient mice did not develop spontaneous
tumors within 2 years after birth. This difference indicates
that, although p53 activity is regulated by p38-PRAK in
ras-induced senescence, p53 and p19ARF likely have
additional tumor-suppressing activities that are not regu-
lated by PRAK. Like many other pathways that mediate
the tumor-suppressing activity of p53, the p38-PRAK-
p53 circuitry may only be essential for tumor suppression
under specific cancer-causing conditions, such as when
oncogenic ras mutations are induced. Our data demon-
strate that this pathway is indispensable in tumor suppres-
sion during ras-driven tumorigenesis.(H) FLAG-mp53 or -mp53S37A was immunoprecipitated from PRAK+/+ or PRAK/ MEFs at passage 4 on day 6 posttransduction of Ha-RasV12
or vector, following in vivo labeling with [32P]phosphorus, and separated by SDS-PAGE. Phosphorylated and total mp53 levels were detected by
autoradiography and western blot, respectively.
(I) PRAK immunoprecipitated from a DMBA-induced PRAK+/+ papilloma (P) or adjacent normal skin (NS) was assayed for kinase activity toward
mp53(1–57) or mp53(1–57)S37A. For all IP kinase assays (A, B, D, H, and I), western blot analysis was performed to detect the indicated proteins
in IPs and lysates. For all kinase assays (A, B, D, E, F, H, and I), relative phosphorylation levels of substrates and substrate inputs are shown.Cell 128, 295–308, January 26, 2007 ª2007 Elsevier Inc. 305
Previous studies on the regulation of p53 in senescence
have focusedmainly on the induction of p53 protein levels.
However, p53 protein levels are unaltered during ras-
induced senescence in some primary cells (Zhu et al.,
1998), including the BJ cells used in this study, suggesting
that the regulation of p53 occurs at posttranslational
levels. Several p53 residues, including Ser15, Ser33, and
Ser46, were shown to be phosphorylated in senescent
cells (Ferbeyre et al., 2002; Bulavin et al., 2002). While
the kinase for Ser15 in senescent cells is unknown,
Ser33 and Ser46 are phosphorylated directly by p38
upon ras activation. Nevertheless, it remains unclear
whether phosphorylation of each site is functionally rele-
vant in senescence. Using a retrovirus-based stable p53
reporter and a binary retroviral vector directing a low level
of p53 expression that is not growth inhibitory, we demon-
strate that PRAK is essential for p53 activation during
premature senescence and that phosphorylation of Ser37,
Ser15, andSer33 is critical for p53 tomediate senescence.
Thus, full activation of p53 in the senescence pathway
may require phosphorylation of multiple sites.
DNA-PK and ATR have been reported to phosphorylate
p53-Ser37 in response to DNA damage (Lees-Miller et al.,
1992; Tibbetts et al., 1999). While we cannot rule out the
possible contribution of DNA-PK and ATR to Ser37 phos-
phorylation in the senescence pathway, PRAK seems to
be the major Ser37 kinase during senescence because
ras-induced Ser37 phosphorylation is essentially abol-
ished in PRAK-deficient human and mouse cells (Figures
7G and 7H). On the other hand, UV-induced Ser37 phos-
phorylation inBJcells (Figure 7G) is unlikely tobemediated
by PRAK since PRAK is not required for DNA-damage-
induced p53 activity and cell-cycle arrest (Figure S7).
Therefore, it is likely that p53-Ser37 phosphorylation is
mediated primarily by different kinases in the DNA-
damage pathway and the senescence pathway.
EXPERIMENTAL PROCEDURES
Cell Culture
BJ and LinX-A cells were maintained as described (Wang et al., 2002).
Primary mouse skin fibroblasts were isolated from 12- to 15-day-old
mice. The skin on the back was excised, washed with PBS, incubated
with 0.05% trypsin-EDTA at 37C for 15 min, minced, and digested in
4ml of 2mg/ml collagenase A (Roche) at 37C for 2–3 hr. The digestion
was stopped by the addition of 10 ml of medium. Cells were collected
and seeded in the medium used for LinX-A. MEFs were isolated from
day 14 embryos using a published protocol (Serrano et al., 1997).
Plasmids
E1A and Ha-RasV12 vectors were obtained from Dr. Scott Lowe (Cold
Spring Harbor Laboratory). Retroviral vectors for HA-hPRAK or
mPRAK were constructed by cloning PRAK cDNA (New et al., 1998;
New et al., 2003) into BabePuro or WZLHygro. Oligonucleotides for
shRNA targeting PRAK (shPK-1, 50-GCTGGAATTAGTGGTCCAG-30;
shPK-2, 50-GTGTCTATATCCACGACCA-30), p53, and GFP (Brummel-
kamp et al., 2002b) were cloned into pSUPER.retro according to
a published protocol (Brummelkamp et al., 2002a). Retroviral vectors
for MKK3/6E (Wang et al., 2002) and MDM2 (Sun et al., 1998) and
retroviral p53 reporter PG-Luc and its non-p53-binding control MG-
Luc (Deng et al., 2005) have been reported previously. To create p53306 Cell 128, 295–308, January 26, 2007 ª2007 Elsevier Inc.expression vectors, p53 cDNA was cloned into pcDNA3, BabePuro,
or a binary vector (GAPDH-PGK-Puro) (Deng et al., 2004). p53mutants
were generated using the QuikChange Site-Directed Mutagenesis
Kit (Stratagene).
Retrovirus-Based Gene Transduction
Retrovirus-based gene transduction was carried out as previously
described (Sun et al., 1998). Transduced cells were purified with
120 (BJ) or 75 (MEF and MSF) mg/ml hygromycin B, 400 mg/ml G418,
5 mg/ml blasticidin, and/or 1.2 mg/ml puromycin.
Western Blot Analysis
Western blot analysis was performed with lysates prepared 6–8 days
after transduction of Ras or MKK3/6E from subconfluent cells as
described (Wang et al., 2002). Primary antibodies were from Covance
(HA-11), Sigma (actin), Santa Cruz (Ras C-20,MKK3C-19,MKK6 V-20,
E2F-1 KH95, cyclin A, p53 FL-393, p21WAF1 C-19, p15 K-18, p16
M-156, p19ARF 5C31, Mcl1 S-19), Cell Signaling (phospho-ERK, phos-
pho-p38, ERK, p38, phospho-p53-Ser15, phospho-p53-Ser33, phos-
pho-p53-Ser37, BAX), Novocastra (p16INK4a DCS-50, p53 CM5), BD
Pharmingen (MCM3), Stressgen (DcR2), and Oncogene Research
Product (PCNA Ab-1). Anti-Dec1 was a gift from Dr. Adrian L. Harris
(Cancer Research UK), and anti-p21 (hp21C) was from Dr. Yanping
Zhang (University of North Carolina). Signals were detected using
enhanced chemiluminescence and captured by the FluorChem 8900
Imaging System (Alpha Innotech).
Analysis of Senescence
Analysis of senescence in cell culture was performed as described
previously (Wang et al., 2002). To quantify SA-b-gal positives, at least
200 cells were counted in random fields in each of the duplicated wells.
To detect SA-b-gal in vivo, 10 mm frozen sections of papilloma or
normal skin were fixed in 0.2% glutaraldehyde/PBS for 10 min at
4C, washed with PBS (pH 6.0), stained with 1 g/l X-gal/1 mM
K4Fe(CN)6/5 mM K3Fe(CN)6/2 mMMgCl2 in PBS (pH 6.0) for overnight
at 37C, washed with H2O, counterstained with eosin, and dehydrated
in an ethanol gradient with toluene. For immunohistochemistry of se-
nescence markers, 8 mm frozen sections of tumors were fixed in 4%
PFA; permeabilized in 0.1% Triton X-100/PBS; blocked in 4% BSA/
0.1% Triton X-100/PBS for 1 hr at room temperature; and incubated
with primary antibodies (Ki-67, Lab Vision, 1:100; DcR2, Stressgen,
1:500; p16 M156, Santa Cruz, 1:500; PRAK, 1:750) in 4% BSA/0.1%
Triton X-100/PBS overnight at 4C, with biotinylated goat anti-rabbit
IgG for 2 hr at room temperature, and finally with ABC-HRP (Vector
Laboratories) for 2 hr at room temperature. The slides were developed
with DAB/H2O2, counterstained with hematoxylin, and dehydrated
with an ethanol gradient and toluene.
Tumorigenesis Assays
BJ and murine fibroblasts were transduced with indicated oncogenes
at PD18.9 and passage 2, respectively. For anchorage-independent
growth, 3–4 3 104 BJ cells at PD25 or mouse fibroblasts at passage
3 were resuspended in a medium containing 0.3% low-melting-point
agarose and plated onto a solidified bottom layer medium containing
0.5% agarose in 6 cm plates. Colonies were photographed after 2–4
weeks, stained with 0.02%Giemsa, and counted. For tumor formation
assays, 23 106 BJ cells at PD28 or 106mouse fibroblasts at passage 4
were injected subcutaneously into the flanks of 6-week-old female
HSD:athymic nude mice in 100 ml of serum-free RPMI1640. Tumor
growth was monitored weekly for 10 weeks. For skin carcinogenesis,
PRAK+/+, PRAK+/, or PRAK/ littermates (129 3 C57BL/6) were
treated with 50 ml of 0.5% DMBA in acetone to the dorsal surface on
postnatal day 1–5 and monitored weekly. For two-stage carcinogene-
sis, mice were treated with 6.25 mg of TPA in 100 ml of acetone twice
a week starting 7 days after DMBA treatment. The Em-N-rasG12D
mice were a gift from Dr. A.W. Harris (Walter and Eliza Hall Institute
of Medical Research, Australia).
p53 Reporter Assays
BJ cells at PD25 were transducedwith PG-Luc or MG-Luc (Deng et al.,
2005); shPRAK, shp53, or shGFP; and Ha-RasV12, MKK3E, MKK6E,
or vector; split into 12-well plates on day 7 post ras transduction;
and lysed on day 8. MEFs were transduced at passage 2 with PG-Luc
or MG-Luc and Ha-RasV12 or vector, split on day 6, and lysed on day
7. Luciferase activity was determined and normalized to protein
concentrations.
Immunoprecipitation/Western Blot Analysis
Immunoprecipitation/western blot analysis was performed as de-
scribed (Deng et al., 2005), except that p53 was immunoprecipitated
from 1 mg of each lysate from subconfluent BJ cells (PD28–30) using
agarose-conjugated anti-p53 DO-1 and Pab1801 (5 mg each).
Recombinant Proteins
pGEX-hp53(FL) was a gift from Dr. Roberta Maestro (CRO, Aviano,
Italy). Recombinant HSP27, GST-ATF2, GST-full-length p53, His-
PRAK, and His-p38 were prepared as described previously (New
et al., 1998; New et al., 2003). hp53(1–61) and mp53(1–54) were coex-
pressed with the ZZTAZ2 domain of CBP from a bicistronic vector to
enhance protein stability and were purified as described (Legge
et al., 2004).
PRAK Kinase Assays
BJ cells were lysed at PD30–40 on day 6–8 post ras/MKK3/6E trans-
duction in buffer containing 50 mM HEPES (pH 7.5), 2.5 mM EGTA,
1 mM EDTA, 1% Triton X-100, 150 mM NaCl, 10% glycerol, 1 mM
PMSF, 50 mM NaF, 1 mM sodium vanadate, 1 mM b-glycerophos-
phate, 1 mM DTT, and Complete protease inhibitors. Cells were
treated with 8 mM of SB203580 for 6–8 days before lysis if necessary.
Papillomas and skin tissues were minced, homogenized, and soni-
cated in the same buffer. One hundred to three hundred micrograms
of lysate was incubated with 60 ml anti-HA antibody 12CA5 or 6 ml
anti-PRAK or anti-p38 antibody (New et al., 1998) at 4C for 2 hr,
followed by incubation with 30 ml of protein G or 40 ml of protein A
Sepharose at 4C for 2 hr. The beads were washed three times with
1 ml of lysis buffer and three times with 13 kinase buffer (50 mM
HEPES [pH 7.5], 0.5 mM EGTA, 10 mM MgCl2, 0.1 mM PMSF, 1 mM
NaF, 0.1 mM sodium vanadate, 0.1 mM b-glycerophosphate, and
1 mM DTT). The reactions were performed in 20 ml of 13 kinase buffer
(above) with 10 mM ATP, 0.5 ml of [g-32P]ATP and 5–10 mg of HSP27,
7–10 mg of GST-p53, hp53(1–61) or mp53(1–57), or 2 mg of GST-
ATF2 at 30C for 45 min. Assays with recombinant kinases were per-
formed at 30C for 2 hr in 20 ml of 13 kinase buffer without EGTA,
containing 10–12 mg of hp53(1–61) or mp53(1–57), 2 mg of His-PRAK
or His-p38, and 0.5 ml of [g-32P]ATP. The reactions were stopped by
7 ml of 43 Laemmli buffer, heated at 95C, and separated by
SDS-PAGE. Radioactive signals were detected by a phosphorimager.
In Vivo Phosphorylation of mp53
PRAK+/+ or PRAK/ MEFs transduced with FLAG-mp53A135V,
FLAG-mp53A135V/S37A, or vector were labeled at passage 4 on
day 6 posttransduction of Ha-RasV12 or vector with 2 mCi of
[32P]phosphorus in 8 ml of medium (with dialyzed FCS) for 5 hr. Cells
were lysed in 200 ml of NETN (Deng et al., 2005). FLAG-mp53 was
immunoprecipitated from 72 mg of each lysate with 36 ml of agarose-
conjugated anti-FLAG M2 antibody (Sigma), separated by SDS-
PAGE, and transferred to a nitrocellulose membrane. Radioactive
signals were detected by a phosphorimager. Total mp53 protein levels
were detected by western blot.
Phosphopeptide Mapping
A published method was followed with minor modifications (MacCoss
et al., 2002). Sixty-three micrograms of hp53(1–61) protein phosphor-
ylated by PRAK or left unphosphorylated was denatured by 8M urea/
100 mM Tris (pH 8.5); reduced; alkylated; and digested with Glu-C,Asp-N, or elastase. Formic acid was added to combined reactions
to a final concentration of 5%. MS analysis was performed using
a nine-step multidimensional separation described previously (Wash-
burn et al., 2001). The spectra were searched with SEQUEST (Eng
et al., 1994) against a combined human/mouse/rat protein database
with or without the addition of 80 on S, T, or Y (phosphorylation) or
with a loss of 18 on S or T (neutral loss of phosphoric acid from
phospho-S or -T).
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures
and 12 figures and can be found with this article online at http://
www.cell.com/cgi/content/full/128/2/295/DC1/.
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